Mark Alan Rosen

faculty photo
Associate Professor of Radiology at the Hospital of the University of Pennsylvania
Medical Staff, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA
Medical Staff, Department of Radiology , Penn-Presbyterian Medical Center, Philadelphia, PA
Medical Staff, Department of Radiology, Pennsylvania Hospital, Philadelphia, PA
Department: Radiology

Contact information
Department of Radiology
Hospital of the University of Pennsylvania
1 Silverstein
3400 Spruce Street
Philadelphia, PA 19104-4283
Office: 215-662-3107
Fax: 215-662-3013
Education:
B.A. (Chemistry)
Amherst College, 1986.
M.D. (Medicine)
Columbia University, 1994.
Ph.D. (Biochemistry)
Columbia University, 1994.
Permanent link
 

Description of Research Expertise

Functional Tumor MR Imaging: DCE-MRI, DWI, MRSI
Morphologic Tumor Response Evaluation

Description of Itmat Expertise

Dr. Rosen is pursuing diagnostic approaches and therapies using magnetic resonance imaging.

Selected Publications

Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, Harlacker K, Flaherty KT, Giantonio BJ, Rosen MA, Divgi CR, Song HK, Englander S, Troxel A, Schnall M, O'Dwyer PJ: Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer 120(1): 77-85, 2014.

Pentlicky S, Rosen M, Coffey PS, Kilbourne-Brook M, Shaunik A, Schreiber CA, Barnhart K: An exploratory, randomized, crossover MRI study of microbicide delivery with the SILCS diaphragm compared to a vaginal applicator. Contraception. 187-92 (eds.). 87(2), 2013.

Busch DR, Choe R, Rosen MA, Guo W, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, Demichele A, Schnall MD, Yodh AG: Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express 4(1): 105-21, 2013.

Ashraf AB, Gavenonis SC, Daye D, Mies C, Rosen MA, Kontos D: A multichannel Markov random field framework for tumor segmentation with an application to classification of gene expression-based breast cancer recurrence risk. IEEE Trans Med Imaging 32(4): 637-48, 2013.

Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA: MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 200(1): 120-6, 2013.

Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD : Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy - Results from ACRIN 6657/I-SPY TRIAL Radiology 263(3): 663-672, 2012.

Xue Y, Yu J, Kang HS, Englander S, Rosen MA, Song HK : Automatic coil selection for streak artifact reduction in radial MRI Magnetic Resonance in Medicine 67(2): 470-476, 2012.

Guzzo TJ, Resnick MJ, Canter DJ, Bivalacqua TJ, Rosen MA, Bergey MR, Magerfleisch L, Tomazewski JE, Wein AJ, Malkowicz SB: Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance Urologic Oncology: Seminars and Original Investigations 30(3): 301-305, 2012.

Rengan R, Mick R, Pryma D, Rosen MA, Lin LL, Maity AM, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Prendergast S, Sharkoski T, Hahn SM.: A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response. Journal Thoracic Oncology 7(4): 709-15. 2012.

Toth R, Bloch BN, Genega EM, Rofsky NM, Lenkinski RE, Rosen MA, Kalyanpur A, Pungavkar S, Madabhushi A: Accurate prostate volume estimation using multifeature active shape models on T2-weighted MRI Academic Radiology 18(6): 745-754, 2011.

back to top
Last updated: 01/05/2014
The Trustees of the University of Pennsylvania